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Abstract
The RNA-binding protein Tristetraprolin (TTP, ZFP36) functions as a tumor
suppressor that impairs the development and disables the maintenance of MYC-
driven lymphoma. In addition, other human cancers expressed reduced levels of
TTP, suggesting that it may function as a tumor suppressor in several malignancies.
To identify genes that may be associated with TTP tumor suppressor functions in
human cancer, we analyzed The Cancer Genome Atlas (TCGA) breast cancer, lung
adenocarcinoma, lung squamous cell carcinoma, and colon adenocarcinoma
datasets. These analyses defined a signature of 50 genes differentially regulated
between high and low TTP-expressing tumors. Notably, patients with low TTP-
expressing breast cancer and lung adenocarcinoma had decreased survival rates
and more aggressive tumors with increased necrosis. In addition, analysis across
non-TCGA tumor gene expression databases identified a broad spectrum of human
cancers having similarities with the TTP-low tumor gene signature, including
pancreatic, bladder, and prostate cancer. TTP has documented roles in regulating
mRNAs encoding inflammatory proteins, and pathway analysis identified several
inflammatory pathways that are altered in tumors with low TTP expression.
Surprisingly, the TTP-low tumor gene signature includes a core component of 20
under-expressed CREB target genes, suggesting that the regulation of CREB
activity may be related to the tumor suppressor function of TTP. Thus, reduced
levels of TTP are a potential biomarker for human cancers with poor outcome, and
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targeting the CREB pathway may be a therapeutic route for treating aggressive
TTP-low tumors.
Introduction
The Cancer Genome Atlas (TCGA) is a comprehensive project aimed at capturing
the genomic and clinical details of more than 20 different types of cancer, with
data from hundreds of patients for each tumor type [1]. Even though specific
anatomical and histological features have historically defined cancer, in this age of
genomics it has become evident that genetic alterations in tumors even within a
given subtype are unique from one patient to another, underscoring the need for
personalized cancer therapies. To move towards the ultimate goal of personalizing
cancer treatment it is necessary to identify novel molecular biomarkers and
therapeutic targets that serve as the basis for developing treatment options.
Accordingly, here we utilized several TCGA datasets to define the gene expression
signature of malignancies that express reduced levels of the newly discovered
tumor suppressor Tristetraprolin (TTP, ZFP36) [2].
TTP functions in the post-transcriptional control of short-lived mRNAs having
adenosine-uridine (AU)-rich elements (AREs) located in their 39 untranslated
regions (39UTRs). Notably, genomic analysis has shown that at least 11% of all
human genes contain AREs, and, pertinent to this study, all ten of the molecular
mechanisms defined as the ‘‘Hallmarks of Cancer’’ include genes that contain
AREs [3, 4]. AREs are bound by a class of proteins, including TTP, called AU-
binding proteins (AUBPs), which either stabilize these transcripts or direct their
destruction [5]. The NMR structure of TIS11D showed that the tandem zinc-
finger domains, common to all TTP family members, bind to the nonameric 59-
UUAUUUAUU-39 motif present in its mRNA targets; however, recent global
analysis has shown that TTP can also bind to shorter ARE regions [6–8]. Upon
binding, TTP transports its cargo to regions of the cell known as processing bodies
(P-bodies), where the mRNA undergoes deadenylation, decapping, and
degradation by a series of mRNA decay enzymes [9]. The role of TTP in post-
transcriptional control was discovered from its ability to directly bind to an ARE
present in the mRNA encoding the inflammatory cytokine tumor necrosis factor-
a (TNFa), thereby promoting the decay of TNFa transcripts [10]. Indeed, TTP
loss in knockout mice leads to supraphysiological levels of TNFa that, in turn,
causes a severe autoimmune disease that manifests as erosive arthritis, dermatitis,
cachexia and myeloid hyperplasia [11]. However, the ability of TTP to bind to
TNFa mRNA can be suppressed by the p38/MK2 pathway, which phosphorylates
and transiently inactivates TTP and causes it to translocate to the cytoplasm,
allowing TNFa to be expressed [12, 13]. Further, several studies have shown
important roles for TTP in regulating other inflammatory cytokines, and these
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have suggested that reduced levels of TTP may contribute to an array of human
diseases where inflammation plays critical roles, including cancer [14].
A variety of tumor types and models have been used to assess the role of TTP in
cancer. In a Myc-driven mouse model of B cell lymphoma, Myc represses TTP
transcription. However, enforcing TTP expression in Myc-expressing B cells
doubles the lifespan of these tumor-prone mice and disables maintenance of Myc-
driven lymphoma; thus, in this scenario TTP functions as tumor suppressor [2].
Further, TTP loss in cervical cancer leads to stabilization of E6-AP ubiquitin ligase
mRNA, and E6-AP triggers p53 degradation and the induction of hTERT,
overriding senescence [15]. Also, reductions of TTP levels in colon cancer have
been shown to lead to increased levels of the inflammatory cytokine COX-2 and
the pro-angiogenic cytokine VEGF [16, 17]. Moreover, low TTP levels correlate
with high tumor grade and poor outcome in human breast cancer patients [18].
Finally, genomic analyses have revealed low levels of TTP in human glioma, head
and neck squamous cell carcinoma, melanoma, and prostate cancer [18–21].
However, the targets of TTP that are required for its tumor suppressor functions
remain undefined.
Here we applied genomic analyses using four TCGA tumor datasets (breast
cancer, lung adenocarcinoma, lung squamous cell carcinoma, and colon
adenocarcinoma) [22–24] to define the mRNA expression signature associated
with reduced TTP levels in human malignancies. These analyses identified a
shared signature, comprised of 50 genes, which are differentially expressed in
high-TTP versus low-TTP expressing tumors. Notably, clinical data associated
with these datasets establish that in some tumor types reduced TTP expression is a
poor prognostic indicator that is associated with more aggressive and necrotic
tumors. Unexpectedly, these analyses revealed that CREB target genes represent a
significant proportion of the TTP-low tumor gene signature, suggesting that
manipulating activity of the CREB pathway is a potential treatment option for
patients with low TTP expressing tumors.
Materials and Methods
The Cancer Genome Atlas (TCGA) Data Retrieval
Breast cancer, lung adenocarcinoma, lung squamous cell carcinoma, and colon
adenocarcinoma were downloaded from the TCGA portal (http://tcga-data.nci.
nih.gov/). For expression profiling analyses, level 3 expression data of 20,475 genes
and 73,599 isoforms from the RNASeqV2 platform were downloaded for each
cancer dataset. For clinical analyses, a clinical matrix dataset was downloaded for
each cancer. The number of samples included in each dataset at the time of these
analyses was: breast cancer, 813; lung adenocarcinoma, 355; lung squamous cell
carcinoma, 260; and colon adenocarcinoma, 193.
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Gene expression profiling analysis
RNA-Sequencing (RNA-Seq) by Expectation-Maximization (RSEM) normalized
count was used to analyze gene-level or isoform level transcription estimates for
the RNASeqV2 data from each TCGA dataset. For each cancer dataset, log2
normalized counts were imported into GeneSpring GX V12.1 (Agilent
Technologies). Baseline transformation was set as the median for all samples.
Upper and lower quartile groups (TTP-high and TTP-low) were defined based on
TTP (ZFP36) expression within each dataset. Out of 20,475 genes in each RNA-
Seq dataset, only genes that expressed higher than median in at least one sample
were filtered for downstream analysis.
The GeneSpring Volcano Plot function was used to identify differentially
expressed genes (DEGs) between the TTP-high and TTP-low groups for each
TCGA dataset. Statistical test parameters were as follows: selected test, unpaired t-
test; p-value computation, Asymptotic; multiple testing correction, Benjamini-
Hichberg. Corrected p-value cut-off was set to 0.05 and fold change cut-off was set
to 2.
The GeneSpring hierarchical clustering algorithm was used to generate
heatmaps. The similarity measure was set to Pearson centered and the linkage rule
was set to average. A Venn diagram was created using GeneSpring GX V12.1
software to evaluate which DEGs overlap between all four datasets to identify the
TTP-low tumor gene signature.
Data from GSE32574 was used for gene expression analysis of unstimulated
versus LPS-treated macrophages [25]. All genes shown on the heatmap were above
the 50th percentile in at least one sample.
Analysis of clinical data
All clinical data analyzed herein are part of open access data generated from
patient samples collected by TCGA. The clinical matrix dataset for each cancer
type downloaded from the TCGA portal included overall survival or relapse-free
survival, tumor subtype, tumor stage and tumor necrosis percentage. The TCGA
breast cancer dataset included data for the presence and absence of estrogen
receptor (ER), progesterone receptor (PR), and human epidermal growth factor
receptor 2 (HER2), along with data for triple negative breast cancers (TNBCs).
TCGA lung adenocarcinoma dataset included mutation data for EGFR, ERBB4,
KRAS and STK11. Clinical data was analyzed for differences between tumors
identified as having high TTP expression versus low TTP expression. Student’s t-
test was used to test for significance (p-value ,0.05) of the tumor necrosis
percentage analysis. Overall survival or recurrence-free survival data of patients
was imported into GraphPad Prism V5.0 software (GraphPad Software, Inc.). The
Mantel-Cox log-rank test (p-value ,0.05) was used to test for significance.
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Identification of tumor sets having similarities to the TTP-low
tumor gene signature
The NextBio Research platform (www.nextbio.com; Illumina, Inc.) was used to
search thousands of human cancer-related mRNA biosets for significant overlap
with the TTP-low tumor gene signature. Tumor sets with at least 10 samples and
25 genes shared with the TTP-low signature list were included in the list of
significantly similar tumor datasets (p-value ,0.05). Fisher’s exact test was used
to calculate the p-values.
Identification of canonical pathways and upstream regulators of
the TTP-low tumor gene signature
Ingenuity Pathway Analysis (IPA) software (Qiagen) was used to identify
canonical pathways having significant overlap and upstream transcriptional
regulators with significantly enriched targets of the TTP-low tumor gene
signature. Fisher’s exact test was used for assessing significance (p–value ,0.05).
Results
Identification of a TTP-low tumor gene signature using The
Cancer Genome Atlas
RNA Sequencing (RNA-Seq) data from TCGA breast cancer, lung adenocarci-
noma, lung squamous cell carcinoma, and colon adenocarcinoma datasets [22-24]
was analyzed, and each tumor type was divided into quartiles based on TTP
expression levels (S1, S2, S3, S4 Tables). The TTP-high (top quartile) and TTP-
low (bottom quartile) groups for each tumor were then analyzed for differentially
expressed genes. These analyses revealed that the expression of hundreds of genes
is altered in each tumor type between TTP-high and TTP-low tumors (Fig. 1; S5,
S6, S7, S8 Tables).
To identify genes whose expression is changed in all four tumor datasets, the
sets of differentially expressed genes were compared, and a set of 50 genes was
identified – the TTP-low tumor gene signature (Fig. 2; Table 1). As predicted, a
large fraction (80%, 40 out of 50 genes) of the mRNAs in the TTP-low tumor gene
signature have AREs in their 39UTRs, including UUAUUUAUU nonamers,
UAUUUAUU octamers and AUUUA pentamers that have been shown to be
bound by TTP in global analyses (Table 1) [8]. Interestingly, though the role of
TTP as an mRNA destabilizing AUBP predicted that TTP-target genes would be
increased in the TTP-low cohort, the expression of all 50 of these signature genes
is markedly reduced in TTP-low tumors compared to TTP-high tumors in the
TCGA breast cancer, lung adenocarcinoma, lung squamous cell carcinoma and
colon adenocarcinoma datasets (Table 2). Thus, other regulatory factors in these
malignancies may be involved in controlling the expression of genes of the TTP-
low tumor gene signature, and it is possible that such factors are common to all
TTP-low tumors (see below).
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Low TTP expression is a poor prognostic indicator in breast
cancer and lung adenocarcinoma
To determine the association of low TTP expression with patient outcome in these
cancers, available TCGA survival data were analyzed between the TTP-high and
TTP-low tumor sets. For the TCGA breast cancer clinical dataset, only a few
overall survival events are currently available [22]. However, relapse-free survival
data is available, and analysis of this data shows that breast cancer patients with
low levels of TTP expression have a higher incidence of relapse than their TTP-
high counterparts (Fig. 3A). This confirms previous findings suggesting that low
TTP expression is a poor prognostic indicator in breast cancer [18].
TCGA data was also used to compare overall survival rates between TTP-high
and TTP-low patients for the three other cancer types. For lung adenocarcinoma,
patients with low levels of TTP expression have decreased survival rates compared
to TTP-high cohorts (Fig. 3B). However, there were no significant differences in
Fig. 1. Differentially expressed genes between tumors in TCGA datasets with high and low expression of TTP. Gene expression profiling showing
differentially expressed genes between TTP-high and TTP-low expressing tumors in TCGA breast cancer (A), lung adenocarcinoma (B), lung squamous cell
carcinoma (C), and colon adenocarcinoma (D) databases. Information regarding the tumor samples in the TTP-high and TTP-low cohorts and the
differentially expressed genes for each tumor type is presented in S1, S2, S3, S4, S5, S6, S7, S8 Tables. All genes shown are hierarchically clustered,
have .2.0-fold change, and are significantly altered by unpaired t-test analysis (corrected p-value ,0.05).
doi:10.1371/journal.pone.0115517.g001
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survival rates of TTP-low versus TTP-high cohorts in lung squamous cell
carcinoma or colon adenocarcinoma patients (Figs. 3C and D). Thus, in some
(e.g., breast cancer and lung adenocarcinoma), but not all, cancer types patients
with tumors having decreased levels of TTP have a worse outcome.
Genomic analysis of human cancer datasets using NextBio Research software
identified another 260 datasets, which compared either cancer tissue to normal
tissue, cancer adjacent tissue to normal tissue, or differential tumor populations,
as having significant similarities to the TTP-low tumor gene signature (S9 Table).
In addition to breast, lung, and colon cancers, other malignancies having
similarities to the TTP-low tumor gene signature include uterine, pancreatic, liver,
bladder and prostate cancers (Table 3). Thus, TTP might be an important
diagnostic biomarker for predicting patient outcome in a broad spectrum of
human tumor types.
Biomarkers in TTP-low breast cancer and lung adenocarcinoma
Specific proteins and/or genes are clinically proven diagnostic markers for
classifying tumor subtypes, predicting patient outcomes, and developing
treatment plans. For example, breast tumors are commonly assessed for three
receptors that are used as pathological biomarkers: the presence or absence of
estrogen receptor (ER) and progesterone receptor (PR), and the enrichment of
human epidermal growth factor receptor 2 (HER2 or ERBB2) [26, 27]. In the
TCGA breast cancer dataset, TTP-low tumors are twice as likely to be ER-negative
(ER-) or PR-negative (PR-) versus TTP-high tumors, indicating that hormone
therapies commonly used to block estrogen activity might be less effective at
Fig. 2. Identification of the TTP-low tumor gene signature. Venn diagram showing the overlap of
differentially expressed genes between TTP-high and TTP-low expressing tumors. The center of the diagram
indicates that there are 50 genes shared by all four cancer datasets that make up the TTP-low tumor gene
signature. These 50 genes are listed in Table 1, and their fold change in each tumor dataset is listed in
Table 2.
doi:10.1371/journal.pone.0115517.g002
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ADAMTS1 Yes 0 1 0 3
ADAMTS8 Yes 0 0 0 1
ADH1B Yes 0 0 0 7
AG2 Yes 0 0 0 3
C16orf89 No 0 0 0 0
C3 No 0 0 0 0
C8orf4 Yes 1 0 0 4
CADM3 No 0 0 0 0
CH25H Yes 0 1 0 2
CSF3 Yes 0 0 0 7
CSRNP1 Yes 1 0 0 3
CTGF Yes 0 0 0 3
CXCL2 Yes 5 2 0 1
CYR61 Yes 0 0 0 5
DUSP1 Yes 2 0 0 1
EDN1 Yes 0 0 1 3
EGR1 Yes 0 0 0 1
EGR2 Yes 0 0 0 2
EGR3 Yes 0 0 0 3
FABP4 Yes 0 0 0 2
FOS Yes 1 0 1 3
FOSB Yes 0 0 0 3
GADD45B No 0 0 0 0
HBA1 No 0 0 0 0
HBA2 No 0 0 0 0
HBB Yes 0 0 0 1
HBEGF Yes 0 1 1 3
HP No 0 0 0 0
IL6 Yes 0 0 2 4
JUN Yes 0 0 1 2
JUNB Yes 0 0 0 2
KLF2 Yes 0 0 0 3
KLF6 Yes 0 0 0 6
NR4A1 Yes 0 0 0 3
NR4A2 Yes 0 0 0 4
NR4A3 Yes 0 0 1 9
OSM Yes 0 0 1 4
PTGDS No 0 0 0 0
PTGS2 Yes 1 1 3 17
RRAD No 0 0 0 0
SCARA5 Yes 0 0 0 2
SELE Yes 0 1 1 6
SERPINE1 Yes 0 0 0 4
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impairing the growth of breast tumors with low TTP expression (Fig. 4A).
Conversely, twice as many TTP-low breast cancers are HER2-positive (HER2+)
compared to the TTP-high cohort, indicating that such patients might have an
improved response to trastuzumab (Herceptin), which targets HER2 [28].
Further, TTP-low breast cancers have approximately two times more triple-
negative breast cancers (TNBCs) than TTP-high tumors. TNBCs lack the presence
of all three receptors, and have limited treatment options and poor overall
outcome [29].
Expression profiling has identified three molecular subtypes of lung
adenocarcinoma, bronchioid, magnoid, and squamoid [30]. EGFR mutations are
more frequent in bronchioid tumors, whereas TP53, KRAS, and STK11 (the gene
encoding the tumor suppressor LKB1) mutations are more frequent in magnoid
tumors [31]. TCGA clinical data was analyzed for mutations of these genes in
TTP-high versus TTP-low lung adenocarcinomas (except for TP53, which was not
included in this dataset [24]). No difference was found for the mutation frequency
of EGFR between the two TTP groups (data not shown). However, the EGFR
family member ERBB4 is less commonly mutated in TTP-low than TTP-high
tumors (Fig. 4B). Similarly, KRAS and STK11 mutations are less frequent in low
TTP-expressing lung adenocarcinomas than in the high TTP-expressing cohort.
Thus, even though the prognosis of patients having TTP-low expressing lung
adenocarcinomas is worse (Fig. 3B), the classifying mutations of this malignancy
are much less frequent in this cohort, suggesting that other alterations, or perhaps
reductions in TTP alone, are drivers of these tumors.
Low levels of TTP correlate with more aggressive subtypes of
breast cancer, lung adenocarcinoma and lung squamous cell
carcinoma
Breast cancer is divided into four molecular subtypes, luminal A, luminal B,
HER2, and basal-like, based on the expression of ER, PR, and HER2 [26, 27].
Luminal A and luminal B are ER-positive (ER+) subtypes, and, in general, luminal













SIK1 Yes 0 0 0 3
SLC6A14 Yes 1 0 0 7
SLIT3 Yes 0 0 0 1
SOCS3 Yes 0 0 2 2
TPSB2 No 0 0 0 0
TTP (ZFP36) Yes 1 0 0 4
VSIG2 Yes 0 0 0 1
aAnnontated by AREsite 1.0 (http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi) [46].
doi:10.1371/journal.pone.0115517.t001
CREB Targets in the TTP-Low Tumor Gene Signature
PLOS ONE | DOI:10.1371/journal.pone.0115517 December 26, 2014 9 / 24




Fold Change in Lung
Adenocarcinoma
Fold Change in Lung
Squamous Cell Carcinoma
Fold Change in Colon
Adenocarcinoma
ADAMTS1 3.18 2.79 2.17 2.48
ADAMTS8 2.53 5.19 2.36 2.03
ADH1B 19.24 9.02 2.96 4.13
AG2 3.22 3.77 3.17 2.63
C16orf89 2.19 3.81 3.21 2.33
C3 2.80 3.09 2.13 2.28
C8orf4 3.26 3.46 2.41 2.64
CADM3 5.81 2.25 2.07 3.39
CH25H 4.62 2.86 2.75 2.25
CSF3 2.16 4.02 6.38 2.84
CSRNP1 2.68 3.20 2.41 2.55
CTGF 3.31 2.38 2.27 2.19
CXCL2 6.61 5.22 4.79 2.41
CYR61 5.23 2.27 2.99 3.53
DUSP1 7.28 6.84 4.19 5.12
EDN1 3.70 2.73 2.46 2.34
EGR1 9.44 4.61 4.17 7.23
EGR2 5.38 2.26 2.11 3.79
EGR3 5.66 3.83 3.21 5.38
FABP4 10.53 3.28 2.86 3.40
FOS 13.74 7.00 5.85 8.08
FOSB 22.65 22.91 7.32 12.64
GADD45B 2.33 2.92 2.45 2.11
HBA1 3.84 6.26 5.01 4.25
HBA2 3.25 4.72 2.65 2.46
HBB 4.23 4.48 2.34 3.30
HBEGF 2.79 2.99 2.30 3.58
HP 3.11 3.21 3.73 2.91
IL6 9.52 2.81 3.14 5.80
JUN 3.68 2.11 2.44 2.04
JUNB 3.53 2.51 2.84 3.41
KLF2 3.23 3.36 2.13 3.00
KLF6 2.19 2.06 2.06 2.31
NR4A1 5.54 7.11 3.77 4.41
NR4A2 2.42 5.52 2.77 2.74
NR4A3 5.00 5.27 3.63 3.77
OSM 2.90 2.42 2.32 3.93
PTGDS 3.80 2.60 2.14 2.19
PTGS2 5.36 2.15 2.07 3.26
RRAD 3.56 2.77 2.97 2.92
SCARA5 7.60 3.80 2.44 2.60
SELE 4.12 2.14 3.03 2.37
SERPINE1 3.72 2.09 2.57 2.95
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versus patients with luminal A tumors [27]. The HER2 and basal-like subtypes are
both ER-negative forms of breast cancer [26]. Further most, but not all, basal-like
breast cancers are also TNBCs [32]. The TCGA breast cancer database includes





Fold Change in Lung
Adenocarcinoma
Fold Change in Lung
Squamous Cell Carcinoma
Fold Change in Colon
Adenocarcinoma
SIK1 2.48 3.30 2.33 2.44
SLC6A14 2.47 3.88 3.29 2.86
SLIT3 2.24 3.00 2.45 2.32
SOCS3 3.41 2.63 2.38 3.27
TPSB2 3.00 2.54 2.26 2.28
VSIG2 3.24 4.19 2.48 4.48
TTP (ZFP36) 8.07 7.32 5.69 4.98
doi:10.1371/journal.pone.0115517.t002
Fig. 3. Low expression of TTP connotes poor outcome for breast cancer and lung adenocarcinoma patients. Relapse-free survival data from TCGA
breast cancer (A) and overall survival data from TCGA lung adenocarcinoma (B), lung squamous cell carcinoma (C), and colon adenocarcinoma (D) was
used to generate Kaplan-Meier survival curves of TTP-high versus TTP-low patients in each dataset. The p-values were determined by the Mantel-Cox log-
rank test.
doi:10.1371/journal.pone.0115517.g003
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Normal gastric tissue tumor adjacent _vs_ normal gastric tissue from healthy individuals 27 1.80E-42
Uterine leiomyomata neoplasm fibroid without 7q deletion _vs_ normal myometrium 37 1.30E-37
Uterine leiomyoma samples _vs_ adjacent normal myometrium 37 4.60E-37
Uterine leiomyomata neoplasm fibroid with 7q deletion _vs_ normal myometrium 31 4.60E-35
Human uterine leiomyomata fibroid _vs_ adjacent normal myometrium_GPL1355 37 8.40E-35
Pancreatic cancer sample _vs_ non-malignant adjacent pancreatic tissue 32 1.20E-33
Uterine cervix - low grade squamous intraepithelial lesions _vs_ normal tissue_GPL571 27 5.70E-32
Adult germ cell carcinoma - Teratoma _vs_ normal testis 46 1.50E-30
Differentiated hepatocellular carcinoma Grade I-II _vs_ normal liver 29 2.30E-30
Soft-tissue samples of all sarcoma patients _vs_ healthy adipose controls 37 1.90E-26
Bladder urothelial cell carcinoma samples _vs_ non-cancerous samples 38 2.30E-26
Human adrenocortical adenoma _vs_ normal adrenal cortex 33 1.30E-25
Adrenal cortex - adrenocortical adenoma _vs_ normal tissue 33 1.30E-25
Prostate Cancer Pathological Gleason Score 8-10 _vs_ Gleason Score 5-6 28 3.00E-25
Soft-tissue samples of malignant fibrous histiocytoma patients _vs_ healthy adipose controls 38 2.10E-24
Soft-tissue samples of MFH-myxofibrosarcoma patients _vs_ healthy adipose controls 35 3.30E-24
Human adrenocortical carcinoma _vs_ normal adrenal cortex 36 1.90E-23
Adrenal cortex - adrenocortical carcinoma _vs_ normal tissue 36 1.90E-23
Soft-tissue samples of leiomyosarcoma patients _vs_ healthy adipose controls 39 3.10E-23
Thyroid tumors _vs_ adjacent matched normal thyroid biopsies 29 3.30E-23
aMinimum 25 genes shared between the bioset and the TTP-low tumor gene signature.
doi:10.1371/journal.pone.0115517.t003
Fig. 4. Differences in breast cancer biomarkers and lung adenocarcinoma mutations based on TTP expression levels. (A) Percentages of estrogen
receptor-negative (ER-), progesterone receptor-negative (PR-), human epidermal growth factor receptor 2-enriched-positive (HER2+), and triple negative
breast cancer (TNBC) patients in the TTP-high and TTP-low TCGA breast cancer sets. (B) Percentages of ERBB4, KRAS, and STK11 mutations in TTP-
high and TTP-low TCGA lung adenocarcinoma patients.
doi:10.1371/journal.pone.0115517.g004
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Fig. 5. Low TTP expression correlates with more aggressive tumor subtypes and advanced tumor stage. Percentages of tumor expression subtypes
(left column) and tumor stage (right column) are shown for patients in the TTP-high and TTP-low groups for TCGA breast cancer (A and B), lung
adenocarcinoma (C and D), lung squamous cell carcinoma (E and F), and colon adenocarcinoma (G and H) datasets.
doi:10.1371/journal.pone.0115517.g005
CREB Targets in the TTP-Low Tumor Gene Signature
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TTP-low quartiles was calculated (Fig. 5A). Comparing these subtypes between
the two groups, only luminal A, the subtype with the best prognosis, has a higher
percentage in TTP-high (71%) than TTP-low tumors (30%). In contrast, in TTP-
low breast tumors, the percentage of luminal B (40%) and basal-like (19%)
subtypes is much higher than in the TTP-high cohort (11% and 7%, respectively).
Finally, patients in the TTP-low group present more with Stage II (62%) and less
with Stage I tumors (11%) compared to the TTP-high patients (55% and 23%,
respectively) (Fig. 5B). Thus, low expression of TTP in breast cancer correlates
with more aggressive tumor types.
Bronchioid lung adenocarcinoma has the most favorable patient outcome of
the three lung adenocarcinoma subtypes [30, 31]. Notably, over 60% of the
patients having high levels of TTP expressed in their tumors were of the
bronchioid subtype, while only 20% of TTP-low patients have this favorable
subtype (Fig. 5C). In contrast, magnoid and squamoid tumors, which have
similar overall survival rates, are much more prevalent in TTP-low lung
adenocarcinoma patients (36% and 44%, respectively) than their TTP-high
counterparts (21% and 18%). This is particularly noteworthy for squamoid lung
adenocarcinoma, as analyses of this subtype have yet to identify any characteristic
genomic alterations [31]. Finally, nearly twice as many TTP-low lung
adenocarcinoma patients have Stage III or Stage IV tumors (27% combined) than
TTP-high patients (14% combined) (Fig. 5D). Therefore, like in breast cancer,
lung adenocarcinomas with low expression of the tumor suppressor gene TTP are
much more likely to have more aggressive and advanced tumors.
There are four expression subtypes of lung squamous cell carcinoma, primitive,
classical, secretory, and basal [33]. The classical, secretory, and basal subtypes have
similar patient outcomes, and the classical form accounts for the largest
percentage of the TTP-low group (43%) versus the TTP-high cohort (30%)
(Fig. 5E). In contrast, secretory or basal lung squamous cell carcinomas were
more likely to have high levels of TTP (27% and 34%, respectively) than tumors
with low TTP (14% and 20%, respectively). Importantly, the primitive subtype of
lung squamous cell carcinoma are poorly differentiated and have the worse
prognosis [33], and patients with low TTP expression have this detrimental form
more often (23%) than individuals with high TTP expression (9%). Finally, lung
squamous cell carcinoma patients with low TTP levels have a higher percentage of
Stage II, III and IV tumors (52% combined) than TTP-high patients (43%
combined) (Fig. 5F). Thus, although there are no differences in overall survival
between TTP-high and TTP-low lung squamous cell carcinoma patients, there are
differences in clinical phenotypes that suggest that reduced TTP expression may
contribute to the aggressiveness of these tumors.
Colon adenocarcinomas are comprised of two biological subtypes, the
microsatellite instability group, which have high levels of hypermethylation, and
the microsatellite stable group, which lack hypermethylation but are chromoso-
mally unstable [23]. There was no difference in the occurrence of these
phenotypes between the TTP-high and TTP-low cohorts in the TCGA colon
adenocarcinoma dataset (Fig. 5G). Further, the stages of colon tumors having
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high and low TTP expression were similar (Fig. 5H). Thus, TTP expression does
not correlate with colon adenocarcinoma subtypes.
TTP-low tumor signature genes affect inflammatory pathways
To identify mechanistic pathways that might be altered in TTP-low tumors,
Ingenuity Pathway Analysis (IPA) software was applied to the gene signature. This
revealed that 16 of the top 20 pathways affected by TTP expression levels are
inflammatory pathways (Table 4, S10 Table) in accord with data showing that
decreased levels of TTP result in increased inflammation [11, 14]. Further, TTP
expression is induced by ligands that trigger the innate immune response [10],
and five of the inflammatory pathways affected by this gene signature are also
innate immunity pathways. Lipopolysaccharide (LPS) is well-established as an
inducer of innate immunity, and gene expression profiling of macrophages
stimulated by LPS compared to unstimulated macrophages [25] found that
several genes in the TTP-low tumor signature are altered during activation of the
innate immune pathway in a fashion similar to cancer based on TTP expression
(S1 Fig.). Finally, 14 of the genes in the TTP-low tumor gene signature are
classified as innate immune genes by the InnateDB database (www.innatedb.com)
[34]. This suggests that TTP is specifically involved in controlling inflammation
that is directed by the innate immune response.
The presence of necrosis within tumors is linked with aggressive disease and
increased inflammation [35, 36]. Indeed, histological examination of tumor
samples in the TCGA datasets revealed that TTP-low breast cancers and lung
adenocarcinomas have significantly more tumor necrosis than TTP-high tumors
(Fig. 6). In contrast, no differences in tumor necrosis were found in lung
squamous cell carcinoma and colon adenocarcinoma. Collectively, these data
suggest that TTP plays a critical role in regulating tumor inflammation in at least
in some malignancies.
CREB target genes are a core component of the TTP-low tumor
gene signature
IPA software was also used to identify transcription factors that control the
expression of the signature genes in tumors with reduced TTP levels. Surprisingly,
the cyclic AMP response element (CRE)-binding protein (CREB) family of
activators (CREB1, CREM, ATF1) was revealed as the top upstream regulator,
where it directly regulates the transcription of 20 out of the 50 genes in the
signature (Table 5; S11 Table; Fig. 7). This suggests a previously unknown
association between the activity of the CREB family of transcription factors and
the ability of TTP to function as a tumor suppressor. All 20 of the CREB targets
were repressed, despite the fact that CREB expression was not significantly altered
in TTP-low versus TTP-high tumors (Fig. 8A; S2 Fig.). However, the expression
level of the CREB family member Activating Transcription Factor 3 (ATF3) was
significantly reduced in TTP-low breast cancer, lung adenocarcinoma and colon
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Table 4. Top 20 canonical pathways significantly altered by the TTP-low tumor gene signature.
Ingenuity Canonical Pathways p-value Inflammatory Pathway
Innate Immune
Pathway
Acute Phase Response Signaling 2.63E-07 Yes No
Glucocorticoid Receptor Signaling 4.79E-06 Yes No
IGF-1 Signaling 5.37E-06 No No
IL-10 Signaling 2.95E-05 Yes No
Role of JAK family kinases in IL-6-type Cytokine Signaling 3.72E-05 Yes No
HMGB1 Signaling 1.02E-04 Yes No
IL-17A Signaling in Fibroblasts 1.05E-04 Yes Yes
HGF Signaling 1.35E-04 No No
Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid
Arthritis
1.38E-04 Yes No
MIF Regulation of Innate Immunity 1.70E-04 Yes Yes
Role of Tissue Factor in Cancer 2.04E-04 Yes No
Corticotropin Releasing Hormone Signaling 2.19E-04 Yes No
IL-6 Signaling 2.40E-04 Yes Yes
Prostanoid Biosynthesis 2.40E-04 Yes No
Hepatic Fibrosis/Hepatic Stellate Cell Activation 4.79E-04 Yes No
Erythropoietin Signaling 7.24E-04 No No
JAK/Stat Signaling 7.24E-04 Yes No
IL-17 Signaling 8.91E-04 Yes Yes
Prolactin Signaling 9.33E-04 No No
Differential Regulation of Cytokine Production in Macrophages and T Helper
Cells by IL-17A and IL-17F
1.00E-03 Yes Yes
doi:10.1371/journal.pone.0115517.t004
Fig. 6. Low TTP levels correlate with increased tumor necrosis in breast cancer and lung
adenocarcinoma. Average percentages of tumor necrosis in TTP-high and TTP-low tumors in TCGA breast
cancer, lung adenocarcinoma, lung squamous cell carcinoma, and colon adenocarcinoma datasets. The p-
values were determined by Student’s t-test (*p,0.05, *** p,0.001).
doi:10.1371/journal.pone.0115517.g006
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adenocarcinoma. Interestingly, ATF3 expression is induced by innate signaling
and functions to harness this response [25, 37]. In scenarios where there is chronic
stimulation of innate immune signaling, such as that provoked by high levels of
necrosis, one would predict innate immune tolerance [38] resulting in reductions
Table 5. Top 10 upstream regulators of the TTP-low tumor gene signature.
















aMinimum 3 genes in the TTP-low tumor gene signature must be targets of the upstream regulator.
doi:10.1371/journal.pone.0115517.t005
Fig. 7. CREB-target genes are a core component of the TTP-low tumor gene signature. Diagram of the
20 CREB-target genes found by Ingenuity Pathway Analysis in the TTP-low tumor gene signature.
doi:10.1371/journal.pone.0115517.g007
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of ATF3 expression, which is precisely what is observed in the necrosis-associated
TTP-low gene expression signature.
Some splice variants of CREB family members function as dominant negative
repressors of CREB activity [39, 40]. Thus, we assessed if the repression of CREB
target genes in the TTP-low tumor gene signature was associated with alterations
in the levels of the well-characterized cAMP Response Element Modulator
(CREM) variant known as Inducible cAMP Early Repressor (ICER). ICER
contains a basic leucine zipper (bZIP) domain that directs binding to CRE sites
but lacks the N-terminal domain that binds to regulatory cofactors necessary for
CREB transcriptional activity (Fig. 8B). ICER expression significantly correlated
with TTP in all four cancer datasets; thus, it is unlikely to impair the
transcriptional activity of CREB family members in TTP-low tumors (Fig. 8C; S3
Fig.). However, the expression of CREM transcript variant 2, which harbors the N-
terminal domain of CREM but lacks the bZIP domain (CREMDZIP) and is
predicted to compete with CREB family members for necessary transcriptional
cofactors (Fig. 8B), was significantly increased in breast cancer, lung adenocar-
cinoma, and lung squamous cell carcinoma having low TTP expression (Fig. 8C).
Therefore, CREMDZIP may impair the transcriptional activity of CREB family
members in some TTP-low cancers and lead to the repression of CREB target
genes in these tumors.
Fig. 8. Expression of CREB family members in breast cancer and lung adenocarcinoma based on TTP
levels. Gene expression profiling showing the expression levels of canonical CREB family members (A), and
comparing the expression levels of CREM versus its dominant negative splice variants ICER and CREMDZIP
(C) in TTP-high and TTP-low expressing TCGA breast cancers and lung adenocarcinomas. (B) Cartoon
showing the canonical CREM protein and its dominant negative splice variants ICER and CREMDZIP.
doi:10.1371/journal.pone.0115517.g008
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Discussion
The identification of the TTP-low tumor gene signature in the TCGA breast
cancer, lung adenocarcinoma, lung squamous cell carcinoma and colon
adenocarcinoma datasets provides new avenues for investigating the functions of
TTP as a tumor suppressor across a broad spectrum of human malignancies. In
some scenarios, such as breast cancer and lung adenocarcinoma, reduced levels of
TTP are associated with worse patient outcome, more aggressive tumor stage and
subtypes, and increased tumor necrosis. In addition, the expression of genes in the
TTP-low tumor gene signature is altered in a similar fashion in hundreds of other
human tumor datasets, including uterine, pancreatic, bladder, liver, and prostate
cancers. For most of these tumor types little is known regarding potential roles of
TTP, and in the case of pancreatic and bladder cancer this is the first time any
connection to TTP has been described. Therefore, TTP should be thoroughly
explored across an array of human cancers, especially in more aggressive subtypes
and/or in tumors having high levels of tumor necrosis, to determine if low TTP
expression levels are a prognostic indicator.
The analyses herein show that the TTP-low tumor gene signature is involved in
inflammatory pathways, particularly innate immunity, and the increased necrosis
in tumors classified as TTP-low supports this notion. Necrotic cells release
endogenous ligands called damage-associated molecular patterns (DAMPs),
which bind to and activate Toll-like receptors (TLRs) to induce the innate
immune response [41]. Initial activation of TLRs triggers an inflammatory
cytokine response, including the induction of TNFa, yet TTP is also induced by
TLRs to harness the expression of these cytokines and control inflammation
[10, 42]. However, subsequent activation of TLRs results in an impaired innate
inflammatory response known as tolerance [38]. Thus, in TTP-low tumors with
high levels of necrosis, it is likely that increased levels of DAMPs are present,
which cause chronic stimulation of TLRs that leads to a tolerant state of the innate
immune pathway and immune suppression. Further studies will determine if
decreased levels of TTP cause the increased levels of necrosis, or if rather decreases
in TTP levels reflect tolerance of the innate immune response.
Gene cluster analysis of kinetic profiles following LPS treatment of macro-
phages revealed that TTP and ATF3 are coordinately and rapidly induced in
response to TLR4-activated innate immunity [25]. Other genes similarly regulated
include DUSP1, EGR1, EGR2, JUN, and NR4A1 [25], which are components of
the TTP-low tumor gene signature, again linking TTP levels and innate immunity.
Similar to TTP function in controlling innate immunity, ATF3 transcriptionally
represses the expression of cytokines, such as IL-6 and IL-12b, to function as a
negative feedback regulator of innate immune-driven inflammation [25]. This
suggests that TTP and ATF3 together harness TLR-mediated inflammation, and
future studies should include tests of their functional relationship and how this
relates to tumor development and progression.
Other connections of CREB in TTP-low expressing tumors also bear further
investigation. First, CREB and TTP may be linked via a common upstream
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regulator, for example p38 mitogen-activated protein kinase (MAPK). In LPS-
treated macrophages, p38 activates its downstream kinase MK2, which stabilizes
TTP mRNA and directly phosphorylates TTP protein regulating its subcellular
localization and stability [13, 43]. Also p38 activates the mitogen- and stress-
activated protein kinases MSK1 and MSK2 that, in turn, induce TTP protein [12].
In addition, MSK1 and MSK2 facilitate the stress-induced phosphorylation of
CREB at Ser-133, which induces the transcription of several immediate early genes
including c-fos, junB, and egr1 [44], which are, notably, part of the low-TTP
tumor gene signature. Therefore, future studies should test if impairing p38
MAPK in tumor cells suppresses both TTP expression and CREB activity. In
addition, given that LKB1 functions in part to prevent CREB target gene
activation [45], the decreased mutation frequency of STK11 (LKB1) in TTP-low
lung adenocarcinomas compared to the TTP-high cohort corresponds with the
observed decrease in CREB-target gene expression in TTP-low tumors.
Furthermore, TTP-low tumors express a novel CREB family member,
CREMDZIP, that most likely functions as a dominant negative repressor of CREM
by acting in a manner similar to ATF3DZIP, an ATF3 isoform that also lacks the
leucine zipper domain. ATF3DZIP is unable to bind to DNA but functions as a
dominant negative of ATF3 by competing for co-factors that ATF3 requires to
repress transcription [40]. Collectively, these links between reduced TTP
expression and repressed CREB activity in cancer support the idea that
therapeutic CREB agonists, for example colforsin, salbutamol, clenbuterol, or
isoprenaline, may show benefit as therapeutics for TTP-low expressing tumors,
particularly ones where there is a decrease in CREB activity.
Supporting Information
S1 Fig. Genes in the TTP-low tumor gene signature are also regulated by
activation of innate immunity by LPS. Gene expression profiling analysis of
GSE32574 shows the expression levels of genes in the TTP-low tumor signature in
unstimulated macrophages versus LPS-treated macrophages. All genes shown
were expressed above the 50th percentile in at least one sample.
doi:10.1371/journal.pone.0115517.s001 (TIF)
S2 Fig. CREB family expression in lung squamous cell carcinoma and colon
adenocarcinoma based on TTP levels. Gene expression profiling showing the
expression levels of canonical CREB family members in TTP-high and TTP-low
expressing TCGA lung squamous cell carcinomas and colon adenocarcinomas.
doi:10.1371/journal.pone.0115517.s002 (TIF)
S3 Fig. Expression of CREM splice variants in lung squamous cell carcinoma
and colon adenocarcinoma based on TTP levels. Gene expression profiling
comparing the expression levels of CREM versus its dominant negative splice
variants ICER and CREMDZIP in TTP-high and TTP-low expressing TCGA lung
squamous cell carcinomas and colon adenocarcinomas.
doi:10.1371/journal.pone.0115517.s003 (TIF)
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S1 Table. TCGA breast cancer tumors in the TTP-high and TTP-low quartiles.
doi:10.1371/journal.pone.0115517.s004 (XLSX)
S2 Table. TCGA lung adenocarcinomas in the TTP-high and TTP-low
quartiles.
doi:10.1371/journal.pone.0115517.s005 (XLSX)
S3 Table. TCGA lung squamous cell carcinomas in the TTP-high and TTP-low
quartiles.
doi:10.1371/journal.pone.0115517.s006 (XLSX)
S4 Table. TCGA colon adenocarcinomas in the TTP-high and TTP-low
quartiles.
doi:10.1371/journal.pone.0115517.s007 (XLSX)
S5 Table. Differentially expressed genes in TCGA breast cancer dataset
between high and low TTP-expressing tumors.
doi:10.1371/journal.pone.0115517.s008 (XLSX)
S6 Table. Differentially expressed genes in TCGA lung adenocarcinoma dataset
between high and low TTP-expressing tumors.
doi:10.1371/journal.pone.0115517.s009 (XLSX)
S7 Table. Differentially expressed genes in TCGA lung squamous cell
carcinoma dataset between high and low TTP-expressing tumors.
doi:10.1371/journal.pone.0115517.s010 (XLSX)
S8 Table. Differentially expressed genes in TCGA colon adenocarcinoma
dataset between high and low TTP-expressing tumors.
doi:10.1371/journal.pone.0115517.s011 (XLSX)
S9 Table. Human cancer datasets with similarities to the TTP-low tumor gene
signature.
doi:10.1371/journal.pone.0115517.s012 (XLSX)
S10 Table. Canonical pathways significantly altered by the TTP-low tumor
gene signature.
doi:10.1371/journal.pone.0115517.s013 (XLSX)
S11 Table. Upstream regulators of the TTP-low tumor gene signature.
doi:10.1371/journal.pone.0115517.s014 (XLSX)
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